Initially approved to treat paroxysmal nocturnal hemoglobinuria and more recently approved for myasthenia gravis and AQp4-IgG positive neuromyelitis optica, anti-C5 acts systemically to inhibit complement activation at the level of the C5-convretase (163). The gene discussed is C5; the disease is neuromyelitis optica.